Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Inclusion Criteria: * HIV-infected men and women at least 18 years of age * On stable HAART for previous three months and without anticipated changes in their HAART regimen throughout the duration of the study * Fasting triglycerides \> 150 mg/dl and \< 1,500 mg/dl * Participants may be on lipid lowering therapy; if on lipid lowering therapy, therapy must be stable for 8 weeks and cannot be changes during the course of the study * Participants may be on beta blockers (e.g., Atenolol, Metoprolol, Propranolol), Estrogens (e.g.,Estinyl;Estrace;Estraderm) and Thiazides (water pills), however therapy with these agents must be stable for 8 weeks before starting the study and cannot be altered while on the study unless deemed medically necessary by the participant's medical provider and approved by Dr. Wanke * Female participants of reproductive age must not be pregnant (negative test) or lactating at screening and throughout the trial and agree to use 2 methods of barrier contraception for the course of the trial and 2 months after the trial unless they are surgically sterilized (tubal ligation or hysterectomy), or post-menopausal with no menses for \> 1 year * Ability to provide consent Exclusion Criteria: * Plasma HIV-1 RNA \> 10,000 * Previous history of atherosclerotic disease or diabetes mellitus * Change in HAART regimen over three months prior to study entry * Change in lipid lowering therapy within 2 months * On chronic anticoagulants such as heparin or coumadin * On fish oil, omega 3 supplements, or Omacor currently or during the past month